200~400% GROWTH
Amazing product gammaCore (nVNS technology) that is FDA approved for certain treatments. At the moment it's a medical device painkiller without the use of medication/drug. Helps avoid many drug-like side effects and inconveniences associated with injectable, inhaled, or pill-based medicines.
The same product and technology is being extended to explore other areas:
electrocore.com/future-developments/pipeline/
Other Positives:
Positive financial guidance for next quarter:
Full-year 2020 Revenue: electroCore anticipates that full-year 2020 revenue will be at the upper end of the previously announced guidance range of $3.3 million to $3.5 million, representing greater than 40% growth over full-year 2019 revenue of $2.4 million.
(globenewswire.com/news-release/2021/01/11/2156220/0/en/electroCore-Provides-Business-Update-and-Select-Financial-Guidance.html)
The same product and technology is being extended to explore other areas:
electrocore.com/future-developments/pipeline/
Other Positives:
- Scottish Health Technology recommendation (seekingalpha.com/news/3653075-electrocore-rallies-on-scottish-health-technology-recommending-gammacore-for-cluster-headache)
- 5 Analysts buy (tipranks.com/stocks/ecor/forecast)
- Centers for Medicare and Medicaid Services (“CMS”) validation (globenewswire.com/news-release/2021/01/19/2160526/0/en/electroCore-Inc-Announces-the-Establishment-of-a-Unique-Level-II-HCPCS-Code-for-Non-Invasive-Vagus-Nerve-Stimulator.html)
Positive financial guidance for next quarter:
Full-year 2020 Revenue: electroCore anticipates that full-year 2020 revenue will be at the upper end of the previously announced guidance range of $3.3 million to $3.5 million, representing greater than 40% growth over full-year 2019 revenue of $2.4 million.
(globenewswire.com/news-release/2021/01/11/2156220/0/en/electroCore-Provides-Business-Update-and-Select-Financial-Guidance.html)
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。